GNNSF
Price:
$1.535
Market Cap:
$3.22B
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome edi...[Read more]
Industry
Biotechnology
IPO Date
2017-09-28
Stock Exchange
PNK
Ticker
GNNSF
According to Genscript Biotech Corporation’s latest financial reports and current stock price. The company's current PE Ratio is -19.19. This represents a change of -96.32% compared to the average of -521.42 of the last 4 quarters.
The mean historical PE Ratio of Genscript Biotech Corporation over the last ten years is 47.98. The current -19.19 PE Ratio has changed -4099.57% with respect to the historical average. Over the past ten years (40 quarters), GNNSF's PE Ratio was at its highest in in the September 2018 quarter at 281.78. The PE Ratio was at its lowest in in the September 2023 quarter at -1389.47.
Average
47.98
Median
21.81
Minimum
-53.78
Maximum
230.61
Discovering the peaks and valleys of Genscript Biotech Corporation PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 218.29%
Maximum Annual PE Ratio = 230.61
Minimum Annual Increase = -138.98%
Minimum Annual PE Ratio = -53.78
Year | PE Ratio | Change |
---|---|---|
2023 | -53.78 | 96.54% |
2022 | -27.36 | 3.03% |
2021 | -26.56 | 103.10% |
2020 | -13.08 | -71.63% |
2019 | -46.10 | -138.98% |
2018 | 118.27 | -34.46% |
2017 | 180.47 | 218.29% |
2016 | 56.70 | -6.49% |
2015 | 60.64 | -73.71% |
2014 | 230.61 | 31.30% |
The current PE Ratio of Genscript Biotech Corporation (GNNSF) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-35.90
5-year avg
-33.38
10-year avg
47.98
Genscript Biotech Corporation’s PE Ratio is less than Telix Pharmaceuticals Limited (119.49), less than Keros Therapeutics, Inc. (-13.00), less than Zentalis Pharmaceuticals, Inc. (-1.39), greater than Innovent Biologics, Inc. (-28.70), less than Oxford Nanopore Technologies plc (0), less than Nuvalent, Inc. (-4.44), greater than Crinetics Pharmaceuticals, Inc. (-33.22), less than Inhibrx Biosciences, Inc. (-17.49), less than Merus N.V. (0.14), less than Lyell Immunopharma, Inc. (-14.44), less than Kronos Bio, Inc. (-1.54), less than AgeX Therapeutics, Inc. (-0.54), less than Lineage Cell Therapeutics, Inc. (-1.48), less than Cadrenal Therapeutics, Inc. Common Stock (-6.44), less than ImmuCell Corporation (-2.43), less than Neoleukin Therapeutics, Inc. (-6.87), less than Nuvation Bio Inc. (-0.98), less than Ovid Therapeutics Inc. (-1.10), less than NextCure, Inc. (-2.80), less than Connect Biopharma Holdings Limited (-0.60), less than null (8.88),
Company | PE Ratio | Market cap |
---|---|---|
119.49 | $4.48B | |
-13.00 | $2.27B | |
-1.39 | $271.28M | |
-28.70 | $7.47B | |
0 | $1.70B | |
-4.44 | $6.23B | |
-33.22 | $5.15B | |
-17.49 | $224.49M | |
0.14 | $3.54B | |
-14.44 | $325.12M | |
-1.54 | $55.49M | |
-0.54 | $27.76M | |
-1.48 | $155.77M | |
-6.44 | $15.15M | |
-2.43 | $27.89M | |
-6.87 | $8.20M | |
-0.98 | $769.36M | |
-1.10 | $83.39M | |
-2.80 | $36.93M | |
-0.60 | $67.78M | |
8.88 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genscript Biotech Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Genscript Biotech Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Genscript Biotech Corporation's PE Ratio?
How is the PE Ratio calculated for Genscript Biotech Corporation (GNNSF)?
What is the highest PE Ratio for Genscript Biotech Corporation (GNNSF)?
What is the 3-year average PE Ratio for Genscript Biotech Corporation (GNNSF)?
What is the 5-year average PE Ratio for Genscript Biotech Corporation (GNNSF)?
How does the current PE Ratio for Genscript Biotech Corporation (GNNSF) compare to its historical average?